Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis

Use of magnetic resonance imaging (MRI)/transrectal ultrasound fusion biopsies to determine the accuracy of multiparametric MRI (mpMRI), using Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2), for detecting clinically significant prostate cancer in the overall gland and specifically...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current problems in diagnostic radiology Jg. 47; H. 6; S. 404 - 409
Hauptverfasser: Nguyentat, Michael, Ushinsky, Alexander, Miranda-Aguirre, Alessandra, Uchio, Edward, Lall, Chandana, Shirkhoda, Layla, Lee, Thomas, Green, Christopher, Houshyar, Roozbeh
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 01.11.2018
Schlagworte:
Adult
Aged
Aged, 80 and over
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging
Male
Middle Aged
Multimodal Imaging
Predictive Value of Tests
Prostatic Neoplasms - diagnostic imaging
Retrospective Studies
Sensitivity and Specificity
Ultrasonography
ISSN:0363-0188, 1535-6302, 1535-6302
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Use of magnetic resonance imaging (MRI)/transrectal ultrasound fusion biopsies to determine the accuracy of multiparametric MRI (mpMRI), using Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2), for detecting clinically significant prostate cancer in the overall gland and specifically the peripheral zone (PZ) and transitional zone (TZ). A retrospective analysis of patients who underwent fusion biopsy identified 137 men with 231 prostate lesions was approved by the Institutional Review Board. Subjects initially classified under PI-RADSv1 criteria were regraded using PI-RADSv2 by a radiologist blinded to PI-RADSv1 score and biopsy results. Spearman correlation, chi-squared, and logistic regression analysis were performed. There was positive correlation between PI-RADSv2 and Gleason scores (P < 0.001). In the PZ, mpMRI demonstrated 100% sensitivity, 100% negative predictive value, and 35.9% positive predictive value, compared to 100%, 100%, and 27.1%, respectively, for TZ lesions. When predicting clinically significant prostate cancer, the PI-RADSv2 area under the curve for TZ lesions was 0.844 (95% CI: 0.753-0.935, P < 0.001) and 0.769 (95% CI: 0.684-0.854, P < 0.001) for PZ lesions. Combining PI-RADSv2 with additional risk factors (body mass index, prostate-specific antigen density, digital rectal examination) improved the area under curve. PI-RADSv2 achieves excellent sensitivity and negative predictive value for both PZ and TZ lesions.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0363-0188
1535-6302
1535-6302
DOI:10.1067/j.cpradiol.2017.10.002